Procoralan plus beta-blockers as first-step therapy in heart failure?

Slides:

Advertisements

Similar presentations

patients, 51 countries, 1139 centers Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari R. Rationale, design, and baseline characteristics of.

Advertisements

Long Distance Titration of Heart Failure Medications by Telephone Calls Anne E. Steckler, RN, Heba Wassif, MD, Kalkidan Bishu, MD, Gardar Sigurdsson, MD,

The Importance of Beta-Blockers in Patients with Heart Failure: A Resynchronization-Defibrillation for Ambulatory Heart Failure Trial (RAFT) Analysis.

Effects of selective heart rate reduction with ivabradine on left ventricular remodelling and function: results from the SHIFT echocardiography substudy.

Discussant Inder Anand, MD, FRCP, D Phil (Oxon.)

Effects of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial -- the Losartan Heart Failure Survival.

Purpose To determine whether metoprolol controlled/extended release

The INTENSIFY study: practical daily effectiveness and tolerance of ivabradine in chronic systolic heart failure in Germany Zugck C, Martinka P, Stöckl.

How do we further reduce angina in patients already treated with a hemodynamic agent? Benefits of adding a metabolic agent to other antianginal drugs (

S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Heart rate reduction with ivabradine and health related quality of life in.

analysis from the SHIFT study

Corlanor® - Ivabradine

Sudden Cardiac Death in Heart Failure Trial Presented at American College of Cardiology Scientific Sessions 2004 Presented by Dr. Gust H. Bardy SCD-HeFTSCD-HeFT.

May 23rd, 2012 Hot topics from the Heart Failure Congress in Belgrade.

Heart Failure and Qof Quiz Justin Walker October 2010.

Heart Failure Ben Starnes MD FACC Interventional Cardiology

ATLAS Clinical Trial Commentary Dr Eric Topol Chairman and Professor, Department of Cardiology Director of the Joseph J Jacobs Center for Thrombosis and.

Which Heart Failure patients will improve their exercise capacity after exercise training ? P Meurin 1, JY Tabet 1.2, A Bendriss 1, F Beauvais 2, H Weber.

CHARM-Alternative: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Alternative Purpose To determine whether the angiotensin.

CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved Purpose To determine whether the angiotensin.

Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose? Systolic.

Effect of ivabradine on recurrent hospitalization for worsening heart failure: findings from SHIFT S ystolic H eart failure treatment with the I f inhibitor.

BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.

European guidelines on the management of stable coronary artery disease Key points & new position for Ivabradine and Trimetazidine ESC 2013 Montalescot.

CIBIS III Ronnie Willenheimer University Hospital, Malmö, Sweden, on behalf of the CIBIS III investigators Results of the randomized Cardiac Insufficiency.

S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Objective, design and baseline Swedberg.

Effect of ivabradine on recurrent hospitalization for worsening heart failure: findings from SHIFT S ystolic H eart failure treatment with the I f inhibitor.

S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Main results Swedberg K, et al. Lancet. 2010;376(9744):

To know more visit HeartFailure.com © 2015 Novartis Pharma AG, May 2015, GLCM/HTF/0028 HEART FAILURE DISEASE MANAGEMENT STANDARDS.

Compliance with clinical practice guidelines for the treatment and optimization of therapy in heart failure patients in outpatient medicine clinics MaryAnn.

BEST: Beta-blocker Evaluation Survival Trial Purpose To determine whether the β-blocker bucindolol reduces morbidity and mortality in patients with advanced.

HOPE: Heart Outcomes Prevention Evaluation study Purpose To evaluate whether the long-acting ACE inhibitor ramipril and/or vitamin E reduce the incidence.

PARADIGM-HF A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to.

Camm J, et al. On Behalf of The SHIFT Gothenburg, Cardiac safety of selective heart rate reduction with Ivabradine in chronic heart failure. Poster, Heart.

CIBIS II Cardiac Insufficiency Bisoprolol Study

S ystolic H eart failure treatment with the If inhibitor ivabradine T rial Michel Komajda and Karl Swedberg on behalf of the Investigators.

Influence of background treatment with mineralocorticoid receptor antagonists on ivabradine's effects in patients with chronic heart failure Systolic Heart.

News You Can Use… Josh Stewart, PharmD Candidate 2016 Pete Koval, PharmD Cone Health Family Medicine October 2015.

COMET: Carvedilol Or Metoprolol European Trial Purpose To compare the effects of carvedilol (a β 1 -, β 2 - and α 1 -receptor blocker) and short-acting.

Heart rate in heart failure: Heart rate in heart failure: risk marker or risk factor? A subanalysis of the SHIFT trial on behalf of the Investigators M.

ELITE - II Study Design  60 yrs; NYHA II - IV; EF  40 % ACEI naive or  7 days in 3 months prior to entry Standard Rx ( ± Dig / Diuretics ), ß - blocker.

CURRENT APPROACH TO THE TREATMENT OF CONGESTIVE HEART FAILURE.

Embargoed Until 3:45 p.m. ET, Sunday, Nov. 8, 2015

Relationship of background ACEI dose to benefits of candesartan in the CHARM-Added trial.

Can we better protect patients who undergo revascularization? Beneficial effects of short- and long-term trimetazidine MR therapy in patients undergoing.

New 2011 SHIFT quality of life substudy Quality of life ( QoL) in heart failure: where do we stand? Therapies that have survival benefits either have a.

COPERNICUS: Carvedilol Prospective Randomized Cumulative Survival trial Purpose To assess the effect of carvedilol, a β 1 -, β 2 - and α 1 -receptor blocker,

HEART FAILURE. Excellent Care 1. Diagnosis 2. ACE-I and B blocker 3. Aldosterone antagonist 4. Exercise 5. Statin and aspirin if CVD 6. Digoxin with AF.

HF diagnosis: audit of NTproBNP uptake and outcomes across Sheffield An update on diagnosis and management of HF Dr Abdallah Al-Mohammad, MD, FRCP(Edin),

Erectile Dysfunction and Cardiovascular Disease. ED and Cardiovascular Diseases.

Ridha Chakeer MD PGY3. Objectives: Approximately 5.2 million Americans are affected  accounts for more than 3 million outpatient visits to primary care.

Date of download: 9/19/2016 Copyright © The American College of Cardiology. All rights reserved. From: Resting Heart Rate in Cardiovascular Disease J Am.

JOURNAL REVIEW HEART FAILURE MANAGEMENT – BETA BLOCKERS

Ivabradine – A new option for Heart Failure Patients

NYHA III* or IV heart failure ACE-I + loop diuretic ± digoxn

A Randomized Clinical Trial

Section III: Neurohormonal strategies in heart failure

SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.

CIBIS II: Cardiac Insufficiency Bisoprolol Study II

PROCAMIO Trial design: Patients with hemodynamically stable wide complex monomorphic tachycardia were randomized 1:1 to either intravenous procainamide.

TACTICS-HF Trial design: Patients with acute heart failure (reduced or preserved ejection fraction) were randomized to tolvaptan 30 mg at 0, 24, and 48.

Anaerobic threshold responder analysis

Section III: Neurohormonal strategies in heart failure

CHAMPION Trial design: Patients with recent hospitalization for heart failure were implanted with a pulmonary artery pressure monitor and randomized so.

The American College of Cardiology Presented by Dr. Timothy Henry

Systolic Heart failure treatment with the If inhibitor ivabradine Trial Effect of ivabradine on recurrent hospitalization for worsening heart failure:

The FAIR-HF Trial Reference

Absolute mortality difference Change in LVEF from baseline

Number of patients who would have benefitted from addition of ACE inhibitor (ACEi), beta blockers (BB) or optimal therapy (one or both of ACEi and BB)

Pro-inflammatory biomarkers in decompensated and stable HFpEF patients

Presentation transcript:

Procoralan plus beta-blockers as first-step therapy in heart failure? Effects of ivabradine plus beta blockers as first step therapy on heart rate, compliance, quality of life and exercise tolerance in patients with chronic heart failure A. Macchi1, I. Franzoni1, I. Rosa1, M.C. Pedrigi1, F. Buzzetti1, R. Gorla1, G.V. Gaudio2, P.G. Camici1, A. Margonato1 1.San Raffaele Hospital, Milan, Italy; 2. Antonio Abate Hospital, Somma Lombardo (VA), Italy

Rationale & objective Rationale Beta-blockers are a cornerstone of chronic heart failure treatment and when added to renin-angiotensin-aldosterone system antagonists further reduce mortality and morbidity. Because of side effects (hypotension, asthenia, dyspnea, claudication), few patients reach optimal doses of beta-blockers and optimal heart rate. Procoralan, which is devoid of effects on hemodynamics and contractility, has proven effective in reducing mortality and hospitalization for heart failure. Objective To evaluate the effects of a combination of beta-blockers and Procoralan versus beta-blockers alone on heart rate, compliance to therapy, quality of life, and exercise tolerance.

Study design Patients Methods 111 patients (87 males, 62±7 years) with stable heart failure (NYHA IIb-III) Ejection fraction <35% Renin-angiotensin-aldosterone system antagonists and diuretics No beta-blockers Heart rate at rest >70 bpm, in sinus rhythm Methods Prospective, randomized, open, blinded end point design study Beta-blockers Baseline Resting heart rate Quality of life, symptoms ETT parameters (modified Bruce protocol) Increase dose of beta-blocker or Procoralan if possible Resting heart rate Quality of life, symptoms ETT parameters (modified Bruce protocol) Procoralan + beta-blockers 3 weeks 6 weeks

(Total exercise duration), min Procoralan plus beta-blocker as first-step combination therapy in heart failure increases exercise capacity TED (Total exercise duration), min P=0.05 The combination of Procoralan with beta-blockers resulted in better exercise tolerance compared with beta-blocker alone Baseline 6 weeks Baseline 6 weeks Procoralan + beta-blockers (n= 56) Uptitration of beta-blockers (n=55) Mean daily dose, mg: 1st group – Procoralan, 12.5; Bisoprolol, 3.6; Carvedilol, 13.4; Nebivolol, 12;5; 2nd group – Bisoprolol, 5.4; Carvedilol, 25.3; Nebivolol, 5.1 Macchi A, et al. Eur Heart J. 2011;32( Abstract Supplement ):641-642; Abs 3720

Procoralan + beta-blockers Uptitration of beta-blockers Procoralan plus beta-blocker as first-step combination therapy in heart failure improves quality of life Quality of life scale P<0.001 Baseline 6 weeks Health-related quality of life assessed using the LVD36 questionnaire and quality of life scale was improved by combination of Procoralan with β-blockers compared with β-blocker alone. Baseline 6 weeks Procoralan + beta-blockers (n= 56) Uptitration of beta-blockers (n=55) Macchi A, et al. Eur Heart J 2011;32( Abstract Supplement):641-642; Abs 3720

Conclusions The combination of Procoralan with a beta-blocker can be introduced safely as first-step therapy in chronic heart failure. This combination ensures optimal heart rate control, and ameliorates exercise capacity and quality of life compared with beta-blocker alone. The combination of Procoralan with a beta-blocker is well tolerated compared with beta-blocker alone.